Advertised cash-pay tirzepatide pricing across tracked providers, sorted low to high, with provenance. This is advertised price, not total cost — see total monthly cost for the dose-dependent picture.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Advertised | Model | Provenance |
|---|---|---|---|
| Fifty 410 | from ~$133 | Dose-tiered | primary |
| Henry Meds | $179 | Flat | secondary |
| NexLife | $186–$215 | Flat | primary |
| Mochi Health | ~$278 eff. | Membership + add-on | secondary |
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.